We Fuel a Network of Leaders that Drive Virginia Bioscience
We are made up of the people who do the research, development and commercialization of biosciences in Virginia, and the suppliers, consultants, attorneys, accountants and others who work to support the industry.
Driven by Innovation & Growth
Our mission is to promote innovation and growth through strengthened networks; advocacy; capital investment; talent attraction, development and retention; and advancing the next generation of leaders.
Virginia's Life Science Community By the Numbers
Life science companies in Virginia.
Life Science contributes $8B to Virginia's economy.
Employed by Life Science companies in Virginia.
$77,848 Average Wage
Average earnings of life science workers in Virginia.
1,197 Clinical trials
Biopharmaceutical industry-sponsored trials in Virginia per year.
Power Surge: Spark Your Company’s Growth with BLUE KNIGHT™
10/25/2021 – 10/25/2021
11:00 am – 11:45 am EST
Bonumose Inc. to invest $27.7M in Albemarle County expansion
Virginia sugar alternatives company Bonumose Inc. will invest $27.7 million to expand in Albemarle County in a partnership with The Hershey Co. to research and develop reduced or zero sugar chocolate products, creating 64 jobs, Gov. Ralph Northam announced. Bonumose will move into 36,000 square feet of the former State Farm building to increase production …
Fralin Biomedical Research Institute officially opens $90 million addition
State and local officials gathered for the grand opening of the newest building at the Fralin Biomedical Research Institute in Roanoke. The COVID-19 pandemic delayed the ribbon-cutting ceremony for the 139,000-square-foot addition, which opened to researchers and staff last summer. The building, located at 4 Riverside Circle on the Virginia Tech Carilion Health Sciences campus, …
Landos Biopharma Announces FDA Clearance of its IND for LABP-104 for the Treatment of Systemic Lupus Erythematosus
Landos Biopharma, Inc. (NASDAQ: LABP), a late clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to discover and develop novel therapeutics for patients with autoimmune diseases, announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for LABP-104, a novel, oral, systemically distributed LANCL2 agonist, for …